4,390 followers
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. A tough evaluation of an effective MM therapy. https://t.co/JEEbpqfo6d
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. A tough evaluation of an effective MM therapy. https://t.co/JEEbpqfo6d
#HealthEconJA Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal https://t.co/mn8WGlL9cn